| Name | Title | Contact Details |
|---|
ECIJA, with more than 25 years of experience, is in the Top 10 of the best firms in Spain, according to the prestigious rankings of Chambers & Partners and The Legal 500 and has established itself in the first place as a full service law firm. It has been recognised by The Lawyer as the best TMT firm in Europe and by the Financial Times as the most innovative firm on continental Europe. Its relevance in the Spanish market has been recognised by Expansión and Forbes, which have recognised it as the best firm in Digital Economy in Spain. ECIJA has a team of more than 200 partners and 1000 professionals globally, distributed in countries such as Spain, Portugal, Colombia, Chile, Honduras, Costa Rica, Dominican Republic, Nicaragua, Guatemala, El Salvador, Puerto Rico, Panama, Mexico, Brazil, Ecuador, Argentina and Uruguay. ECIJA is a full-service firm, with core practices in Corporate, M&A, Commercial and TMT, and large labor, litigation and tax groups. The Firm has offices in Spain, Portugal, USA, Central & Latin America and collaborates in all EU and worldwide jurisdictions. The Firm started in the year 1997 and has grown since then to become a full service Firm with presence in all areas of law and sectors. Our Legal Services include: Private Corporate Law, including: -Mergers and Acquisitions (M&A) -Private Equity and Venture Capital -General Corporate Law -Banking Law -Capital Markets -Competition Law and European Law -Human Resources & Employment Benefits -IT, Media, Data Protection and IP Law -Litigation and Arbitration -Project Finance -Public Law -Real Estate and Planning Law -Risk & Compliance -Tax To discuss how ECIJA attorneys can assist you and your business, please visit our website (www.ecija.com)
NuVision Auto Glass is one of the fastest growing auto glass companies in the US. Over 100K happy drivers. Rated 4.5⭐ on Google Serving Arizona, Florida and South Carolina
Health In Tech is an insurtech company focused on enhancing the self-funding process in the healthcare sector. The company aims to create efficient and innovative solutions that benefit individuals and businesses while improving the health insurance landscape. It operates a dynamic marketplace that utilizes third-party AI technology to deliver customized solutions. The company offers a variety of proprietary digital platforms and services that streamline the quoting and underwriting processes for brokers, third-party administrators, and insurers. Key offerings include reference-based pricing, group insurance captives, community health plans, and the eDIYBS platform for small and medium-sized employers. Additionally, the Health Intelligence Card and HI Performance Network are designed to improve the management of medical records and claims while providing cost-effective healthcare options. Health In Tech, Inc. is publicly traded on NASDAQ under the ticker symbol HIT and was founded in 2014. The company is led by CEO Tim Johnson and has around 80 employees.
Hustle Nation Podcast covers everything from leadership to finances, culture, sales, coaching, and personal branding, and most importantly we discuss topics that deliver results. We bring the hustle from the people who have it to the people who need it. We do this by interviewing highly successful leaders, entrepreneurs, and coaches. Our guests share their stories of adversity and success along with their tactics and strategies for crushing success. Its our personal goal to turn our listeners into Hustle Nation advocates and advocates into success stories. So stop reading and start listening.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.